NCT00374296 2015-07-01
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Mirati Therapeutics Inc.
Phase 2 Terminated
Clinical Trials
3 trialsNCT00431873 2015-07-01
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00666497 2015-05-08
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
Phase 2 Terminated